Condition: Idiopathic Pulmonary Fibrosis · Sponsor: Wuhan Optics Valley Vcanbiopharma Co., Ltd.
This study is a single-arm, multiple-dose, dose-escalation, open-label multicenter clinical trial, aiming to evaluate the safety, tolerability, and preliminary efficacy of VUM02 Injection for treatment of idiopathic pulmonary fibrosis (IPF). VUM02 Injection (Human Umbilical Cord Tissue-derived Mesenchymal Stem Cells Injection, hUCT-MSC) is an allogeneic cell therapy product comprising culture-expanded Mesenchymal Stem Cells derived from the human umbilical cord tissue. The product is cryopreserved with the amount of 5 x 10\^7 cells per 10 mL per bag (5 x 10\^6 cells/mL). This study is a multiple-dose tolerability study following the "3+3" dose escalation principle and progressing from the low-dose group to the high-dose group sequentially. Three to six patients will be enrolled in each dose group and administered every 3 days for a total of 3 doses.
This description comes directly from the study's public registry record.
Yuan Peng, Master · +86-27-87002897 · pengyuan@vcanbio.com
Always discuss trial participation with your own doctor first.
| Peking University Third Hospital | Beijing, China | Recruiting |
| West China Hospital of Sichuan University | Chengdu, China | Recruiting |
| The First Affiliated Hospital of Guangzhou Medical University | Guangzhou, China | Recruiting |
| The First People's Hospital of Kashi Prefecture, Xinjiang | Kashgar, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06230822